{
    "clinical_study": {
        "@rank": "23308", 
        "arm_group": {
            "arm_group_label": "Test and reference formulations", 
            "arm_group_type": "Experimental", 
            "description": "Test formulation and reference formulation given orally 14 days apart in a fasted state"
        }, 
        "brief_summary": {
            "textblock": "This study investigates safety and pharmacokinetic comparison of G-0081, a combination\n      tablet of amlodipine and valsartan (test formulation), and Exforge\u00ae, a combination tablet of\n      amlodipine and valsartan (reference formulation) for single dose in healthy volunteers"
        }, 
        "brief_title": "Safety and Pharmacokinetic Comparison of Exforge\u00ae and G-0081 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers between the ages of 20 and 50 and within 20% of their ideal\n             body weight, without congenital abnormality or chronic disease\n\n        Exclusion Criteria:\n\n          -  History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal,\n             hematologic, neurologic or hemorrhagic disease;\n\n          -  Clinically significant findings on routine laboratory (hematology, serum chemistry\n             and urinalysis) or ECG tests;\n\n          -  Use of prescription drugs in the 14 days immediately prior to starting the study that\n             had the potential to interact with the study medication;\n\n          -  Use of any substance that could induce or inhibit drug metabolism enzymes"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823913", 
            "org_study_id": "G-0081"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test and reference formulations", 
                "description": "A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg", 
                "intervention_name": "Test formulation", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Test and reference formulations", 
                "description": "A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg", 
                "intervention_name": "Reference formulation", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics", 
        "lastchanged_date": "April 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cmax, Area Under Curve(0 to the last sampling time)", 
            "measure": "Profile of Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 144, 192 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823913"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Severance Hospital", 
            "investigator_full_name": "Kyungsoo Park", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Tmax, Area Under Curve(0 to infinity), T_1/2", 
            "measure": "Profile of Pharmacokinetics", 
            "safety_issue": "No", 
            "time_frame": "0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 144, 192 hours post-dose"
        }, 
        "source": "Severance Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Severance Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}